Company: FVN
Filing Date: 2025-04-14
Form Type: DRS/A
Source: 0001829126-25-002616
Chunk: 216

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-04-14
Form: DRS/A
Chunk 216
---
 as comparative financial information of VIWO (the acquirer for accounting purposes).

Regulatory Approvals

The Business Combination and the other transactions contemplated by the Merger Agreement are not subject to any additional federal or state regulatory requirements or approvals, including the Hart-Scott Rodino Antitrust Improvements Act of 1976. Consummation of the Business Combination (and the issuance of the shares to the VIWO shareholders) will require a declaration of effectiveness of the Proxy Statement/Prospectus, listing approval from the Nasdaq Stock Market Inc., and filing of the Plan of Merger with the Cayman Registry.

VIWO will be required to complete securities filing with the China Securities Regulatory Commission to consummate the Business Combination. Please see “Risk Factors — The filing, approval or other administration requirements of the Chinese Securities Regulatory Commission (the “CSRC”) or other PRC government authorities may be required in connection with our future offshore offering under PRC law, and, if required, we cannot predict whether or for how long we will be able to complete the filing procedure with the CSRC and obtain such approval or complete such filing, as applicable”

<div align='center'>125</div>

<div align='center'>THE MERGER AGREEMENT</div>

The following is a summary of the material provisions of the Merger Agreement, a copy of which is attached as Annex A to this proxy statement and the First Amendment. You are encouraged to read the Merger Agreement, as amended, in its entirety for a more complete description of the terms and conditions of the Business Combination.

Merger with VIWO; Consideration

Upon the closing of the transactions contemplated in the Merger Agreement (the “Closing”), VIWO will become a wholly-owned subsidiary of Future Vision. The consummation of the transactions contemplated by the Merger Agreement are referred to collectively as the Business Combination. Merger Sub will merge with and into VIWO with VIWO surviving the merger. The former shareholders of VIWO will receive 9,950,250 ordinary shares of Future Vision.

Assuming (i) there are no redemptions of the public shares, (ii) the issuance of 9,950,250 Future Vision ordinary shares to the VIWO shareholders pursuant to the Merger Agreement, (iii) the issuance of Future Vision Shares upon the conversion of the Future Vision public and private rights and (iv) 28,750 Ordinary Shares issuable as deferred underwriting commission of the IPO, Future Vision will have an aggregate of approximately 18,127,899